1970
DOI: 10.1212/wnl.20.5_part_2.1
|View full text |Cite
|
Sign up to set email alerts
|

Cooperative study in the evaluation of therapy in multiple sclerosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
18
0

Year Published

1972
1972
2020
2020

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 175 publications
(18 citation statements)
references
References 0 publications
0
18
0
Order By: Relevance
“…The National Cooperative Clinical Trial4547 assessed therapeutic response to a 2-week course of RCI IM (vs placebo) in treating 197 relapse-remitting patients with acute MS relapses; no relapse definition was provided. In the RCI group, a consistently larger proportion of patients showed improvement (≥1-unit change DSS) at 1, 2, 3, and 4 weeks after initiation of treatment with RCI versus placebo (RCI: 38%, 57%, 61%, and 65%; placebo: 26%, 38%, 49%, and 48%, respectively).…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…The National Cooperative Clinical Trial4547 assessed therapeutic response to a 2-week course of RCI IM (vs placebo) in treating 197 relapse-remitting patients with acute MS relapses; no relapse definition was provided. In the RCI group, a consistently larger proportion of patients showed improvement (≥1-unit change DSS) at 1, 2, 3, and 4 weeks after initiation of treatment with RCI versus placebo (RCI: 38%, 57%, 61%, and 65%; placebo: 26%, 38%, 49%, and 48%, respectively).…”
Section: Resultsmentioning
confidence: 99%
“…No statistical differences were observed between groups. IVIG vs placebo, with IVMP add-on TARIMS Study (2004)41N=76Mean age, years: IVIG, 35.3; placebo, 35.2 ( P =0.99)Germany, Denmark, Sweden Intervention IVIG followed by IVMP 24 hrs later (n=36) vs placebo followed by IVMP 24 hrs later (n=40) Treatment duration NRPatients with ≥1 AE, n (%): IVIG, 26 (72); placebo, 30 (75)No patients discontinued because of AEsNROverall, the treatment was well tolerated.Visser et al (2004)42N=19Mean age, years: IVMP followed by IVIG, 37.5; IVMP, 38.1The Netherlands Intervention IVMP followed by IVIG (n=10) vs IVMP followed by placebo (n=9) Treatment duration 5 daysAEs NRNo SAEs occurredNRNo SAEs occurred. However, there was not enough information on safety assessment to conclude whether the treatments were well tolerated. RCI National Cooperative Clinical TrialHenderson et al (1978)45Rose et al (1969)46Rose et al, 197047N=197Age: NRUS Intervention RCI IM (n=103) vsPlacebo (n=94) Treatment duration: 14 daysRCI: 44% (53% females, 28% males) with AEsPlacebo: 9% with AEs ( P ≤0.05)No SAE in either group RCI Acne: 30.9%Hirsutism: 6.8%Moon face: 6.8%Weight gain: 4.9%Impaired glucose tolerance: 4.9%Peptic ulcer or GI bleeding: 1.0%Severe depression: 1.0%Striae of subcutaneous tissue: 0 Placebo Acne: 2.1%Hirsutism: 1.1%Peptic ulcer or GI bleeding: 3.2%Severe depression: 1.1%Striae of subcutaneous tissue: 1.1%No SAEs in either group; AEs present in 44% of patients on RCI, significantly more than the 9% of those on placebo, of which the most common was acne 46Simsarian et al (2011)48N=20Age: 39.5US Intervention RCI SC (n=10) vs RCI IM (n=10) Treatment duration: 5 daysSevere AE SC (n=1): 10%Severe AE IM (n=1): 10%No SAEs in either groupNRInjections were well tolerated in both groups, with an equivalent proportion of patients affected by severe AEs in each group Abbreviations: AE, adverse event; COPOUSEP, Corticothérapie Orale dans les Poussées de Sclérose en Plaques; EPO, erythropoietin; IA, immunoadsorption; IM, intramuscular; IV, intravenous; IVIG, intravenous immunoglobulin; IVMP, intravenous methylprednisolone; NR, not reported; OMP, oral methylprednisolone; OPT, oral prednisone taper; PMP, plasmapheresis; RCI, repository corticotropin injection; SAE, serious adverse event; tx, treatment; US, United States.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…Numerous studies have demonstrated that RCI treatment increases recovery rates and improves disability scores in patients experiencing acute MS relapse exacerbations [15][16][17][18][19][20]. Other studies assessing the economic benefits of RCI have found that RCI treatment for MS relapse is associated with fewer hospitalizations and outpatient service visits as well as lower costs in inpatient and outpatient services when compared to alternative second-line treatments [21,22].…”
Section: Introductionmentioning
confidence: 99%